
Lycia Therapeutics, Inc.
LYCAPricedLycia Therapeutics, Inc. · Nasdaq Global Market · Research source · S-1 · 2026-10-05 · Latest filing · 8-K · 2026-10-26 SEC ↗
Lycia’s preliminary IPO remains incomplete, with blank pricing, share counts, proceeds and listing approval pending.
As of the October 5, 2026 preliminary prospectus, Lycia had not disclosed IPO pricing or share counts and had no public market.
- Business and development direction
Lycia Therapeutics, Inc.
Current business Future development
Key risks
Risk 1
Lycia has limited operating history, no approved products and has not completed any clinical trials, making success difficult to evaluate.
Risk 2
The company expects significant future losses and substantial additional capital; failure to raise funds could delay or eliminate programs.
Risk 3
Clinical, regulatory, intellectual-property and third-party manufacturing failures could prevent commercialization or increase costs and delays.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Source-linked structured inputs are not yet available. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | Jefferies LLC | |||
| 2 | TD Securities (USA) LLC | |||
| 3 | Evercore Group L.L.C. | |||
| 4 | Guggenheim Securities, LLC | |||
| 5 | LifeSci Capital, LLC | |||
| 6 | Jefferies | |||
| 7 | TD Cowen | |||
| 8 | Evercore ISI | |||
| 9 | Guggenheim Securities | |||
| 10 | Passive Book-Running Manager | |||
| 11 | LifeSci Capital |
IPO CAPITAL QUALITY
Basis and evidence
S-1 · 2026-10-05
As of the October 5, 2026 preliminary prospectus, Lycia had not disclosed IPO pricing or share counts and had no public market.
Offering structure
Source and calculation
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Open filing ↗Basis and evidence ↗
Share-count comparison
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Source ↗IPO valuation scenario simulator
Source inputs required
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible whole-issuer pre-offer and post-offer share counts are missing; holder, class-only or offered-share counts cannot substitute for them.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Source-linked structured inputs are not yet available. Open filing ↗ |
- As of
- 2026-10-05
Relationship filters
Select for details · Lycia Therapeutics, Inc.
Holdings and voting rights
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLCOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Redmile Biopharma Investments III, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Venrock Healthcare Capital Partners EG, L.P. and Venrock Healthcare Capital Partners XP, L.P.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd.Ownership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Janus Henderson Biotech Innovation Master Fund LimitedOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| entities with which certain of our directors are affiliatedOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable |
Source and calculation ↗
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(1)Consists of shares of our Series C Preferred Stock purchased by Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLC, which together beneficially own more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(2)Consists of shares of our Series C Preferred Stock purchased by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd., which together beneficially own more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(3)Consists of shares of our Series C Preferred Stock purchased by Redmile Biopharma Investments III, L.P., which beneficially owns more than 5% of our outstanding capital stock. Ming Fang, a member of our board of directors, is affiliated with Redmile Biopharma Investments III, L.P.
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(1)Consists of shares of our Series D Preferred Stock purchased by Venrock Healthcare Capital Partners EG, L.P. and Venrock Healthcare Capital Partners XP, L.P., which together beneficially own more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(2)Consists of shares of our Series D Preferred Stock purchased by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd., which together beneficially own more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(3)Consists of shares of our Series D Preferred Stock purchased by Janus Henderson Biotech Innovation Master Fund Limited, which beneficially owns more than 5% of our outstanding capital stock.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding common stock; not an additive ownership partition
In connection with our Series D Preferred Stock Financing, we entered into the IRA with certain holders of our convertible preferred stock, including entities with which certain of our directors are affiliated and who hold more than 5% of our outstanding common stock. Under the IRA, these stockholders are entitled to rights with respect to the registration of their shares under the Securities Act following this offering, and the provisions relating to registration rights included in the IRA will not terminate as a result of this offering. See the section titled “Description of Capital Stock—Registration Rights” for additional information.
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Source context: The following description summarizes the most important terms of our capital stock, as will be in effect following this offering. Because it is only a summary, it does not contain all the information that may be important to you. We expect to adopt a restated certificate of incorporation and restated bylaws that will become effective upon the completion of this offering, and this description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Conditional lock-up duration
Company, officers, directors and holders of substantially all securities; after date of prospectus
| Measure | Reported value |
|---|---|
| Conditional lock-up duration | 180 days |
Source and calculation
Company, officers, directors and holders of substantially all securities; after date of prospectus
SHARES ELIGIBLE FOR FUTURE SALE ↗Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Each of our officers, directors and substantially all of our stockholdersAfter date of this prospectus · Source conditions apply | 180 days |
| We, our officers, directors and holders of substantially all of our securities,After date of this prospectus · Source conditions apply | 180 days |
Source and calculation
Based on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.
SEC lock-up paragraph; source 693851:695920; SHA256 f452dcb2f163012b8d06835ace45dcfe70f773d9be10b82832dea01db77e12fe ↗We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”
SEC lock-up paragraph; source 1724951:1726308; SHA256 1d6399656e9544a0323570188a3e73821568a4f321ed2a6dc66e46fd6da3aa50 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- Each of our officers, directors and substantially all of our stockholdersBased on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.
- We, our officers, directors and holders of substantially all of our securities,We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”
| Holder / event | Term / date | Conditions |
|---|---|---|
| Each of our officers, directors and substantially all of our stockholders | 180 days | Based on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act. |
| We, our officers, directors and holders of substantially all of our securities, | 180 days | We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.” |
Basis and evidence
Based on shares of our capital stock outstanding as of June 30, 2026, upon completion of this offering, we will have a total of shares of common stock outstanding. Of these shares, only the shares of common stock sold in this offering, or shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after this offering. Each of our officers, directors and substantially all of our stockholders have entered into lock-up agreements with the underwriters that, among other things and subject to certain exceptions, restrict their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, Jefferies LLC and TD Securities (USA) LLC may, in their sole discretion, permit our officers, directors and other stockholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of June 30, 2026, approximately up to an additional shares of common stock will be eligible for sale in the public market approximately of which shares are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act.
SEC lock-up paragraph; source 693851:695920; SHA256 f452dcb2f163012b8d06835ace45dcfe70f773d9be10b82832dea01db77e12fe ↗We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the lock-up period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See the subsection titled “Registration Rights” below and the section titled “Description of Capital Stock—Registration Rights.”
SEC lock-up paragraph; source 1724951:1726308; SHA256 1d6399656e9544a0323570188a3e73821568a4f321ed2a6dc66e46fd6da3aa50 ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | ($26,503,000) | ($36,460,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2024-12-31 | $30,591,000 |
| Cash and cash equivalents2025-12-31 | $19,268,000 |
| Current assets2024-12-31 | $139,828,000 |
| Current assets2025-12-31 | $80,632,000 |
| Total assets2024-12-31 | $150,911,000 |
| Total assets2025-12-31 | $97,215,000 |
| Current liabilities2024-12-31 | $23,327,000 |
| Current liabilities2025-12-31 | $6,486,000 |
| Total liabilities2024-12-31 | $26,499,000 |
| Total liabilities2025-12-31 | $8,213,000 |
| Total equity / (deficit)2024-12-31 | ($77,929,000) |
| Total equity / (deficit)2025-12-31 | ($113,339,000) |
| Cash and cash equivalents2025-12-31 · Unaudited | $19,268,000 |
| Cash and cash equivalents2026-06-30 · Unaudited | $60,940,000 |
| Current assets2025-12-31 · Unaudited | $80,632,000 |
| Current assets2026-06-30 · Unaudited | $127,719,000 |
| Total assets2025-12-31 · Unaudited | $97,215,000 |
| Total assets2026-06-30 · Unaudited | $156,760,000 |
| Current liabilities2025-12-31 · Unaudited | $6,486,000 |
| Current liabilities2026-06-30 · Unaudited | $10,138,000 |
| Total liabilities2025-12-31 · Unaudited | $8,213,000 |
| Total liabilities2026-06-30 · Unaudited | $11,845,000 |
| Total equity / (deficit)2025-12-31 · Unaudited | ($113,339,000) |
| Total equity / (deficit)2026-06-30 · Unaudited | ($132,141,000) |
| Net income / (loss)6M ended 2025-06-30 · Unaudited | ($25,624,000) |
| Net income / (loss)6M ended 2026-06-30 · Unaudited | ($19,196,000) |
Basis and evidence
Financial quality and runway
Financial quality and runway
The latest supplied actual financial period is the six months ended June 30, 2026, supplemented by cash as of that date; the September 30 estimate is blank and unaudited.
EvidenceFinancial review 1Six-month 2026 collaboration revenue was $0 and net loss was $19.196 million, with figures presented in thousands.
+
Six-month 2026 collaboration revenue was $0 and net loss was $19.196 million, with figures presented in thousands.
EvidenceFinancial review 2Cash, cash equivalents and marketable securities were $148.1 million as of June 30, 2026.
+
Cash, cash equivalents and marketable securities were $148.1 million as of June 30, 2026.
EvidenceFinancial review 3The company states it has incurred significant operating losses and has not generated product-sales revenue.
+
The company states it has incurred significant operating losses and has not generated product-sales revenue.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
S-10001628280-26-064973 ↗
Loading filing history…
Lycia has limited operating history, no approved products and has not completed any clinical trials, making success difficult to evaluate.
- Evidence
- Summary Risk Factors ↗
The company expects significant future losses and substantial additional capital; failure to raise funds could delay or eliminate programs.
- Evidence
- Summary Risk Factors ↗
Clinical, regulatory, intellectual-property and third-party manufacturing failures could prevent commercialization or increase costs and delays.
- Evidence
- Summary Risk Factors ↗